Artrya Limited (AYA) Earnings Call Transcripts

11 earnings calls from November 2024 to July 30, 2026

ASX AU Health Care Health Care Technology

Artrya Limited's Latest Earnings Call - Q4 FY2025

In the fourth quarter of 2025, Aya Gold & Silver Inc. reported record revenues of $75 million, significantly up from $34 million in Q1, driven by strong operational performance and increased silver prices. The company achieved a net income of $18 million, marking a substantial turnaround from a loss in the previous year. Management provided guidance for 2026, projecting silver production between 5.2 million and 5.8 million ounces, indicating confidence in operational stability and market conditions.

Reported metrics

MetricValueContext
Revenue $202 million (beat) vs $39 million in 2024, +418% YoY
Net Income $46 million (beat) vs a loss of $26 million in 2024
Operating Cash Flow $72 million (beat) vs negative $9 million in 2024
Earnings Per Share (EPS) $0.32 (beat) vs a loss in the previous year
Milling Rate 3,800 tonnes/day (positive) up from 2,800 tonnes/day at the start of the year
Recovery Rate 91.2% (positive) up from low 80s in Q1 2025

Guidance from management

Management expects to produce between 5.2 million and 5.8 million ounces of silver in 2026, with cash costs projected at $21.50 per ounce for Zgounder and $10 for Boumadine. This guidance reflects a conservative outlook based on the current mining plan.

What management said

Yes. Thanks, Justin. It's a very, very good question and very current question. We're on that on a regular basis, I'll turn this over to Ygo and ugo go and Rahael are managing that part you can imagine of the PEA. So Ugo, do you want to go ahead?
— Benoit La Salle, Q4 FY2025 earnings call
but Justin, Just in the PEA, the payability was established at 73%. Since then, they had revised their offer to 75% payability, and there's no long-term agreement yet signed because they're indicating to us that this will also improve as Ugo said considerably. So we're keeping all of the options open. We have an agreement that is signed for the Boumadine tailings because that is being exported every quarter right now...
— Benoit La Salle, Q4 FY2025 earnings call

What analysts pressed on

Analysts expressed concerns regarding potential bottlenecks in the fast-tracking of the Boumadine feasibility study and the impact of rising fuel prices on cash costs. There was also discussion about the company's disciplined approach to M&A opportunities in Morocco.

Main topics on the call

Read the full Artrya Limited transcript (Q4 FY2025) → Summary generated from the call transcript; every figure above is stated by management on the record.

About Artrya Limited

Artrya Limited (AYA) is a publicly listed company in the Health Care Technology industry, within the Health Care sector. It trades on ASX and is based in AU. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 11 calls on record spanning November 14, 2024 to July 30, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.

Earnings Call History

EarningsCalls.dev has 11 Artrya Limited earnings call transcripts on record, spanning November 14, 2024 to July 30, 2026. Based on this history, Artrya Limited reports quarterly. The most recent call on file is dated July 30, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker
AYA
Exchange
ASX
Country
AU
Sector
Health Care
Industry
Health Care Technology
Calls on record
11
First call
November 14, 2024
Most recent
July 30, 2026
Reporting cadence
quarterly
Quarter Date
Q4 FY2026 Jul 30, 2026 Read transcript
Q1 FY2026 May 14, 2026 Read transcript
Q3 FY2026 May 1, 2026 Read transcript
Q4 FY2025 Mar 31, 2026 Read transcript
Q1 FY2026 Oct 29, 2025 Read transcript
Q3 FY2025 May 1, 2025 Read transcript
Special Calls Mar 31, 2025 Read transcript
Q4 FY2024 Mar 28, 2025 Read transcript
Q2 FY2025 Feb 3, 2025 Read transcript
Shareholder/Analyst Calls Nov 28, 2024 Read transcript
Q3 FY2024 Nov 14, 2024 Read transcript